



Can continuous glucose monitoring predict cystic fibrosis-related diabetes and worse clinical outcome?

Mariana Zorron¹, Fernando Augusto Lima Marson², André Moreno Morcillo¹,
Aline Cristina Gonçalves¹, Mayra de Souza El Beck¹, José Dirceu Ribeiro¹,
Antonio Fernando Ribeiro¹

Table S1. Individual descriptive continuous glucose monitoring (in mg/dL) variables at baseline.^a

P	CGM (T0)	OGTT (T0)	OGTT (T1)	Mean sensor	Min	Max	Valleys		Peaks		% time			AUC		
							< 54	≥ 140	≥ 200	< 54	≥ 140	≥ 200	< 54	≥ 140	≥ 200	
1	CFRD	NGT	NGT	109	40	400	2	12	2	1	14	4	0	10	6	
2	CFRD	NGT	NGT	104	53	306	1	8	3	0	12	3	0	6	2	
3	CFRD	IGT	IGT	103	40	267	4	13	2	7	14	3	1	4	1	
4	CFRD	NGT	NGT	103	40	224	6	15	2	3	9	1	0	2	0	
5	IGT	NGT	NGT	104	80	281	0	4	1	0	4	1	0	1	0	
6	IGT	IGT	IGT	91	73	213	0	2	1	0	2	0	0	0	0	
7	IGT	NGT	IGT	110	64	198	0	9	0	0	11	0	0	2	0	
8	IGT	IGT	NGT	103	72	193	0	5	0	0	7	0	0	1	0	
9	IGT	NGT	IGT	99	55	191	0	6	0	0	8	0	0	2	0	
10	IGT	NGT	IGT	101	59	191	0	4	0	0	4	0	0	1	0	
11	IGT	NGT	CFRD	107	47	188	2	13	0	1	12	0	0	2	0	
12	IGT	NGT	NGT	93	65	179	0	2	0	0	1	0	0	0	0	
13	IGT	NGT	NGT	86	40	178	5	5	0	4	4	0	0	1	0	
14	IGT	NGT	IGT	101	48	170	1	7	0	0	6	0	0	1	0	
15	IGT	NGT	NGT	100	46	167	2	4	0	1	5	0	0	1	0	
16	IGT	IGT	CFRD	92	51	166	2	4	0	1	4	0	0	0	0	
17	IGT	NGT	IGT	100	78	165	0	2	0	0	3	0	0	1	0	
18	IGT	IGT	NGT	103	60	164	0	1	0	0	2	0	0	0	0	
19	IGT	NGT	NGT	101	66	160	0	3	0	0	1	0	0	0	0	
20	IGT	NGT	IGT	102	71	156	0	1	0	0	1	0	0	0	0	
21	IGT	IGT	NGT	95	59	152	0	1	0	0	1	0	0	0	0	
22	IGT	IGT	NGT	99	60	151	0	1	0	0	1	0	0	0	0	
23	IGT	IGT	CFRD	98	58	150	0	2	0	0	1	0	0	0	0	
24	IGT	NGT	NGT	92	70	146	0	1	0	0	0	0	0	0	0	
25	IGT	IGT	IGT	88	50	145	1	1	0	1	1	0	0	0	0	
26	IGT	NGT	NGT	102	78	143	0	1	0	0	0	0	0	0	0	
27	NGT	NGT	NGT	91	73	133	0	0	0	0	0	0	0	0	0	
28	NGT	NGT	IGT	106	78	132	0	0	0	0	0	0	0	0	0	
29	NGT	NGT	NGT	93	67	129	0	0	0	0	0	0	0	0	0	
30	NGT	NGT	NGT	89	64	128	0	0	0	0	0	0	0	0	0	
31	NGT	NGT	NGT	82	50	122	1	0	0	1	0	0	0	0	0	
32	NGT	IGT	IGT	99	57	119	0	0	0	0	0	0	0	0	0	
33	NGT	NGT	NGT	91	59	118	0	0	0	0	0	0	0	0	0	
34	NGT	NGT	NGT	79	63	98	0	0	0	0	0	0	0	0	0	

P: patient; CGM: continuous glucose monitoring; OGTT: oral glucose tolerance test; T0: baseline; T1: end of follow-up; Min: minimum; Max: maximum; CFRD: cystic fibrosis-related diabetes; NGT: normal glucose tolerance; and IGT: impaired glucose tolerance. ^aCGM classification based on OGTT cutoff values.

Table S2. Comparison of FEV₁ (in % of predicted values) and BMI (in kg/m²) at baseline (T0) and at the end of the follow-up period (T1), as well as of their difference (T1 – T0) in relation to the results of the oral glucose tolerance test at T0.^a

Variable	Group		p*
	Impaired glucose tolerance (n = 10)	Normal glucose tolerance (n = 24)	
FEV ₁ (T0)	63.5 (31-99)	75 (18-113)	0.467
FEV ₁ (T1)	53 (18-96)	55 (16-112)	0.752
FEV ₁ (T1 – T0)	–6 (–52 to 24)	–4 (–63 to 19)	0.752
BMI (T0)	15.96 (12.81-21.82)	17.93 (12.39-30.17)	0.254
BMI (T1)	17.07 (14.05-21.89)	17.58 (14.05-31.04)	0.401
BMI (T1 – T0)	0.77 (–2.05 to 4.29)	0.58 (–3.53 to 2.93)	0.491

^aValues expressed as median (minimum-maximum values). *Kruskal-Wallis test ($\alpha = 0.05$).